干细胞补充输注（SCB）治疗复发/难治性多发性骨髓瘤（RRMM）患者 CAR-T 细胞治疗（CAR-T）相关血液学毒性的疗效——美国多发性骨髓瘤免疫治疗联盟的真实世界经验

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refracto

桥接治疗在复发/难治性多发性骨髓瘤患者接受 CAR-T 细胞治疗前的疗效和安全性

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

在接受 B 细胞成熟抗原靶向 CAR-T 细胞治疗的多发性骨髓瘤患者中平衡疗效与安全性

Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen-Directed CAR T-Cell Therapy.

CTLA4 和 LAG3 单核苷酸多态性对接受 BCMA CAR-T 细胞治疗的多发性骨髓瘤患者的临床影响

Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy.

在我们的研究中，CTLA4 rs231775 和 LAG3 rs870849 的次要等位基因与 RRMM 患者接受 BCMA 靶向 CAR-T 细胞治疗后的更优临床结局相关。

CAR-T 细胞治疗前基于苯达莫司汀的淋巴细胞清除：一项系统综述

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.

克隆性造血和炎症预测 B 细胞成熟抗原靶向 CAR-T 细胞治疗后的血液学毒性和继发性髓系恶性肿瘤

Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen-Directed Chimeri

本研究强调了血液学毒性和克隆性造血对 B 细胞成熟抗原 CAR-T 结局的影响，并提示 CAR-T 可能影响 TP53 克隆动态和髓系疾病发展的潜在作用。

功能性高危疾病与多发性骨髓瘤后线 CAR-T 细胞治疗后不良结局相关

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

预测多发性骨髓瘤 BCMA 靶向 CAR-T 细胞治疗后结局与毒性的纵向单细胞图谱

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma.

缓解转换驱动多发性骨髓瘤 CAR-T 细胞治疗后的结局：一项来自 DRST 的注册研究分析

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST.

多发性骨髓瘤细胞治疗背景下通过调节 E3 连接酶底物靶向降解 IKZF1 和 IKZF3

Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma.